Glaucoma Clinical Trial
Official title:
Vitreopapillary Traction and Optic Disc Morphology in Healthy Subjects, Vitreomacular Traction Patients and Glaucoma Patients
The vitreous fills the posterior chamber of the eye and is firmly attached, at the posterior pole, to the macula and the optic nerve head (ONH). With formation of a stepwise posterior vitreous detachment (PVD) exerted tractional forces could influence retinal functioning. Especially in patients with glaucoma the influence of vitreous traction to the ONH could mask progression, interfere with current imaging techniques and even be a cause of ONH hemorrhages. Therefore the aim of this study is to investigate whether vitreopapillary traction has a significant effect on diagnosis and follow up of glaucoma patients.
The vitreous body fills the posterior chamber of the eye and consists mainly of water. It is
kept organized into a gel like structure by numerous collagen fibrils and makes contact with
the surrounding retina. This interplay known as the vitreo-retinal interface of the human
eye is a complex organization of bridging molecules anchoring the vitreous to the internal
limiting membrane. With ageing, the vitreous gel undergoes liquefaction accompanied by
progressive weakening of the adhesions at the vitreo-retinal interface resulting in a
stepwise process of adhesion release. Since the most firm attachments in the posterior pole
are situated at the macular and papillary region, tractional forces exerted during vitreous
separation could influence retinal functioning.
Up until now researchers have been looking primarily at the influence of vitreous traction
to the macular region of the nerve fiber layer.This research has led to the insight that
vitreo-macular traction can result in macular hole formation, and that patients with this
condition may benefit from vitreolysis induced by surgery (vitrectomy) or intravitreal
injection of ocriplasmin.
More recent reports have focused on the influence of the vitreous on the morphology of the
optic disc, showing that VPT altered optic disc architecture, increased average and temporal
retinal nerve fiber layer thickness and was associated with more pronounced visual field
defects. This could be important as very sensitive scans and diagnostic algorithms were
developed for staging and follow up of glaucoma patients' optic nerve head, which could be
influenced by the patients' vitreopapillar interface. As the status of this interface
changes over time, this could lead to confusion and misinterpretation of the optic disc
diagnostic scans.
Besides the diagnostic challenges induced by the vitreopapillar interaction, this interface
may also be of pathogenetic relevance in glaucoma. Indeed, the optic disc represents the
collection of all ganglion cell axons, and glaucoma is caused by a degeneration of ganglion
cells. Some authors have already suggested that vitreopapillary traction (VPT) could play a
role in the pathogenesis of optic nerve head hemorrhages, which are regarded as an important
risk factor for glaucoma progression. Moreover, one could hypothesize that VPT can cause
stress to the ganglion cell axons and therefore contribute more directly to ganglion cell
degeneration.
Accordingly, this study aims at investigating the effect of VPT on the ultra-structural
level of the optic disc. A possible structure-function relation will be investigated with
the help of central visual field tests and focal retinal nerve fiber layer thickness
assessment. With increasing knowledge and imaging of VPT, possibly a VPT-staging algorithm
can be developed and VPT risk factors defined. Finally, this project may have a therapeutic
impact, since it will shed light on the question whether (surgically or chemically) induced
vitreolysis might be beneficial in some glaucoma patients with VPT.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 |